| |
Intervention
|
Control
| | | | |
|---|
|
Clinical topic
|
n
|
Mean before (sd)
|
Mean after (sd)
|
n
|
Mean before (sd)
|
Mean after (sd)
|
Ba (95% CI)
|
icc
|
Direction
|
p
|
|---|
|
Anaemia
|
|
Iron preparations, oral
|
39
|
25.0 (20.7)
|
45.1 (40.0)
|
49
|
27.4 (28.4)
|
49.2 (55.7)
|
3.9 (−13.9, 21.5)
|
0.21
|
=
|
0.644
|
|
Urinary tract infections
|
|
Antibiotics UTI
|
39
|
43.5 (31.6)
|
47.3 (36.5)
|
49
|
47.5 (38.7)
|
59.7 (48.7)
|
11.9 (−3.2, 27.0)
|
0.21
|
↓
|
0.113
|
|
Prostate complaints
|
39
|
59.1 (43.3)
|
107.1 (69.6)
|
49
|
66.5 (58.6)
|
127.5 (102.2)
|
20.0 (−20.9, 60.8)
|
0.38
|
↓
|
0.306
|
|
Alpha receptor blockers
|
39
|
49.6 (35.7)
|
86.6 (56.2)
|
49
|
55.0 (49.5)
|
103.3 (81.5)
|
18.5 (−15.3, 52.3)
|
0.42
|
↓
|
0.258
|
|
5 alpha reductase inhibitors
|
39
|
9.5 (9.5)
|
20.4 (18.6)
|
49
|
11.5 (11.2)
|
24.2 (24.7)
|
1.4 (−7.2, 10.0)
|
0.01
|
↓
|
0.735
|
|
Stomach complaints
|
49
|
329.7 (286.9)
|
612.0 (477.0)
|
39
|
282.6 (210.1)
|
491.8 (333.4)
|
106.7 (−70.7, 284.2)
|
0.63
|
↓
|
0.219
|
|
H2 antagonists
|
49
|
27.8 (26.4)
|
32.4 (30.0)
|
39
|
22.3 (20.5)
|
21.3 (16.4)
|
12.5 (−1.8, 26.8)
|
0.44
|
↑
|
0.081
|
|
Proton pump inhibitors
|
49
|
300.8 (262.9)
|
578.3 (452.3)
|
39
|
259.4 (192.3)
|
469.1 (322.1)
|
93.7 (−71.9, 259.4)
|
0.62
|
↓
|
0.246
|
|
Misoprostol
|
49
|
0.1 (0.4)
|
0.0 (0.2)
|
39
|
0.1 (0.4)
|
0.2 (0.5)
|
−0.1 (−0.2,−0.0)
|
0.00
|
↓
|
0.008 b
|
|
Triple therapy (ATC A02BD04)
|
49
|
1.0 (1.7)
|
1.3 (2.0)
|
39
|
0.9 (1.3)
|
1.1 (1.7)
|
0.2 (−0.7, 1.2)
|
0.49
|
↓
|
0.593 b
|
|
Thyroid dysfunction
|
49
|
81.3 (66.3)
|
137.2 (102.6)
|
39
|
71.4 (48.9)
|
107.1 (71.6)
|
21.2 (−14.1, 56.6)
|
0.42
|
=
|
0.217
|
|
Thyroid hormones
|
49
|
74.8 (60.8)
|
125.0 (92.6)
|
39
|
66.9 (47.4)
|
100.8 (70.0)
|
18.2 (−16.0, 52.4)
|
0.45
|
=
|
0.269
|
|
Antithyroid preparations
|
49
|
6.5 (8.6)
|
12.2 (17.8)
|
39
|
4.5 (4.4)
|
6.3 (7.3)
|
2.6 (−1.7, 7.0)
|
0.09
|
↑
|
0.218 b
|
|
Perimenopausal complaints
|
49
|
56.4 (42.7)
|
56.8 (41.8)
|
39
|
46.3 (34.2)
|
46.0 (29.6)
|
6.6 (−12.0, 25.2)
|
0.56
|
↓
|
0.459
|
|
Oestrogens, oral
|
49
|
14.1 (13.6)
|
12.7 (12.1)
|
39
|
12.3 (11.8)
|
11.2 (10.4)
|
0.2 (−3.6, 4.1)
|
0.01
|
↓
|
0.889
|
|
Contraceptives (>50y)
|
49
|
3.6 (3.2)
|
6.4 (4.9)
|
39
|
3.2 (3.9)
|
5.9 (4.2)
|
1.1 (−1.9, 4.2)
|
0.34
|
↓
|
0.431
|
|
Hormone replacement therapy
|
49
|
34.8 (28.6)
|
34.7 (27.0)
|
39
|
28.3 (19.7)
|
26.3 (17.8)
|
5.8 (−6.5, 18.0)
|
0.70
|
↓
|
0.331
|
|
Clonidine
|
49
|
0.5 (1.8)
|
0.5 (2.0)
|
39
|
0.2 (0.5)
|
0.4 (2.0)
|
0.1 (−1.0, 1.2)
|
0.13
|
↓
|
0.908 b
|
|
Tibolon
|
49
|
3.4 (4.1)
|
2.4 (2.7)
|
39
|
2.3 (2.8)
|
2.2 (3.4)
|
−0.3 (−1.4, 0.8)
|
0.00
|
↓
|
0.615
|
- The desired direction of change is given in the column headed ‘Direction’. Numbers represent the number of DDDs prescribed per 6 months per 1000 patients
-
n = number of practices
-
aAdjusted difference between groups at end of intervention, corrected for baseline
-
bstatistically significant interaction
- Misoprostol
- P 10: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
- P 90: B (95% CI):−0.1 (−0.2,−0.0). p: 0.039
- Triple therapy (ATC A02BD04)
- P10: B (95% CI): 0.9 (−0.2, 1.9). p: 0.117
- P90: B (95% CI):−0.4 (−1.6, 0.7). p: 0.413
- Antithyroid preparations
- P10: B (95% CI):−1.9 (−7.2, 3.4). p: 0.474
- P90: B (95% CI): 12.3 (4.6, 19.9). p: 0.002
- Clonidine
- P10: B (95% CI): 0.6 (−0.4, 1.6). p: 0.215
- P90: B (95% CI):−2.4 (−3.9,−1.0). p: < 0.001
